South & Central America Eye Drops Market
South & Central America Eye Drops Market is growing at a CAGR of 4.4% to reach US$ 1,439.20 million by 2030 from US$ 1,017.09 million in 2022 by Type, Application and Purchase Mode.

Published On: Nov 2023

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
South & Central America Eye Drops Market

At 4.4% CAGR, the South & Central America Eye Drops Market is projected to be worth US$ 1,439.20 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the South & Central America eye drops market was valued at US$ 1,017.09 million in 2022 and is expected to reach US$ 1,439.20 million by 2030, registering a CAGR of 4.4% from 2022 to 2030. Rising prevalence of ophthalmic diseases and high incidence of age-related eye diseases are the critical factors attributed to the South & Central America eye drops market expansion.

Eye diseases hold a substantial share in lifestyle diseases due to the increased use of smartphones, laptops, and computers. The modern lifestyle, which involves increased screen time, is responsible for triggering eye-related problems. Eye health is significantly compromised in this technological era. Working on computers for a long time eventually affects the health of the eyes. Individuals with chronic eye problems and refractive errors are at higher risk of developing digital eye strain (DES). 

Extreme exposure to blue rays emitting from smartphones, tablets, iPads, and laptops also causes serious eye damage. Due to the COVID-19 outbreak, all companies opted for work-from-home (WFH) to prevent the spread of COVID-19. The growing trend of WFH has intensified the screen time of working professionals, further accelerating the number of eye-related issues. According to a study published by Frontiers, the repeated use of digital devices for more than two continuous hours is putting the user at a great risk of developing DES due to the excessive accommodative demands. Although the spread of COVID-19 has been controlled to a large extent, many companies have allowed their employees to continue with WFH to decrease the overall expenditure. This flexibility with regard to work location has led to an increase in screen time. Such lifestyle changes will eventually damage eye health, generating a greater demand for eye drops.

On the contrary, product recalls hamper the South & Central America eye drops market. 

Based on type, the South & Central America eye drops market is segmented into antibiotics, artificial tears, hormones, and others. The antibiotics segment held 38.6% share of South & Central America eye drops market in 2022, amassing US$ 392.98 million. It is projected to garner US$ 566.36 million by 2030 to expand at 4.7% CAGR during 2022–2030.

Based on application, the South & Central America eye drops market is segmented into eye diseases, eye care, and others. The eye diseases segment held 63.9% share of South & Central America eye drops market in 2022, amassing US$ 649.98 million. It is projected to garner US$ 910.91 million by 2030 to expand at 4.3% CAGR during 2022–2030. The eye diseases segment is further segmented into dry eye, glaucoma, cataract, and others.

Based on purchase mode, the South & Central America eye drops market is segmented into OTC and prescription. The prescription segment held 60.3% share of South & Central America eye drops market in 2022, amassing US$ 613.19 million. It is projected to garner US$ 887.49 million by 2030 to expand at 4.7% CAGR during 2022–2030.

Based on country, the South & Central America eye drops market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 66.7% share of South & Central America eye drops market in 2022. It was assessed at US$ 678.60 million in 2022 and is likely to hit US$ 978.51 million by 2030, exhibiting a CAGR of 4.7% during 2022–2030.      

Key players operating in the South & Central America eye drops market are AbbVie Inc, Alcon AG, Bausch & Lomb Inc, Pfizer Inc, and Rohto Pharmaceutical Co Ltd, among others.

  • In May 2023, Bausch + Lomb Corporation received FDA Approval for MIEBO (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only FDA-approved treatment for DED that directly targets tear evaporation.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com